A Phase I trial of telaglenastat in combination with the mTOR inhibitor sapanisertib in patients with advanced NSCLC is currently underway (Clinicaltrials.Gov: NCT04250545) [103], the results of which will be eagerly awaited. This evidence concerns the gene MTOR and non-small cell lung carcinoma.